GLP-1 obesity drugs like Wegovy and Zepbound are silencing the relentless internal dialogue known as 'food noise,' prompting scientists to reexamine the biological roots of weight regulation. For decades, researchers focused on dosing and side effects, ignoring the psychological battle many face. Now, patients like Lena Smith Parker describe a life without food noise as 'my brain is empty'—a phenomenon experts attribute to the drugs’ potential to reset the body’s weight 'set point.' Dr. Lee Kaplan of Boston’s Obesity and Metabolism Institute links this to 1940s studies showing animals and humans naturally revert to a preferred weight, suggesting obesity stems from a malfunctioning set point. Dr. Jules Hirsch’s 1970s research on semi-starvation neurosis revealed how weight loss triggers metabolic slowdowns and obsessive food thoughts, creating a cycle of regain.

GLP-1s appear to disrupt this by lowering the set point, though experts caution effects may reverse if treatment stops. Oprah Winfrey’s public account of losing food noise highlights the drugs’ transformative potential, while Dr. Daniel Drucker questions how they interact with the set point mechanism. The $30 billion obesity drug market is now racing to understand these dynamics, with implications for long-term treatment strategies.